

Data Sheet

Product Name: Angiotensin II 5-valine


Cat. No.: CS-5786 CAS No.: 58-49-1

Molecular Formula: C49H69N13O12

Molecular Weight: 1032.15

Target: Angiotensin Receptor Pathway: GPCR/G Protein

Solubility: $H2O : \ge 257.5 \text{ mg/mL } (249.48 \text{ mM})$



BIOLOGICAL ACTIVITY:

Angiotensin II 5-valine is an agonist of **angiotensin receptor**. IC50 & Target: Angiotensin receptor^[1]. **In Vivo**: By day 12, systolic blood pressure (SBP) increases significantly in Angiotensin II 5-valine infused rats (197±7 mm Hg). As shown, the development of hypertension in ANG II infused rats is prevented by losartan treatment. Blood and kidney samples are harvested, subjected to HPLC to separate Angiotensin II 5-valine (exogenous) from Ile5-ANG II (endogenous) and the fractions are measured by radioimmunoassay. In the Angiotensin II 5-valine infused rats treated with losartan, total plasma ANG II levels are elevated to a greater extent than in rats not treated with losartan (289±20 v 119±14 fmol/mL). However, losartan markedly decrease by 88% the enhancement of intrarenal Val5-ANG II content that occurred in the rats infused with Val5-ANG II alone^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: [1] Rats[1]

Male Sprague Dawley **rats** are uninephrectomized and divided into three groups: control (n=6), Angiotensin II 5-valine (exogenous form) infused (n=8), and **Angiotensin II 5-valine** infused rats treat with losartan (n=8). Angiotensin II 5-valine, which has the same biological and immunoreactive properties as endogenous ANG II, was infused at 40 ng/min via an osmotic minipump implant subcutaneously^[1].

References:

[1]. Zou LX et al. Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. Am J Hypertens. 1998 May;11(5):570-8.

CAIndexNames:

Angiotensin II, 5-L-valine-

SMILES:

O = C(N(CCC1)[C@@H]1C(N[C@H](C(O) = O)CC2 = CC = CC2) = O)[C@@H](NC([C@H](C(C)C)NC([C@H](NC([C@H](C(C)C)NC([C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C)C)NC([C@H](C(C)C)NC([C@H](C(C)C)NC([C(C)C)NC([C@H](C(C)C)NC([C)C)NC([C@H](C(C)C)NC([C(C)C)NC([C)C)NC([C@H](C(C)C)NC([C)C)NC([C@H](C(C)C)NC([C)C)NC([C)C)NC([C@H](C(C)C)NC([C)C)NC([C)C)NC([C(C)C)NC([C

Page 1 of 2 www.ChemScene.com

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.ChemScene.com